WENZHOU,áChina, June 18, 2018 /PRNewswire/ --áHebron Technology Co., Ltd. ("Hebron" or the "Company") (Nasdaq: HEBT), a developer,manufacturer and installer of valves and pipe fittings for use in the pharmaceutical, biological, food and beverage, and other clean industries , today announced its participation in the ACHEMA Frankfurt 2018 International Exhibition-Congress ("ACHEMA")
ACHEMA, held every 3 years, is an internationally renowned conference focused on chemical engineering, process engineering and biotechnology. The 2018 event attracted 3,737 exhibition stands from across the world. The expo promotes exchange and cooperation between manufacturers and users in the chemical, pharmaceutical, and food industries worldwide, and showcases innovative technologies and development in the industry.á
Hebron exhibited its comprehensive technical services and competitive product lines at ACHEMA. Hebron participated in the event to open overseas international trade markets, exchange advanced technologies and product services in the pharmaceutical industry, and promote the internationalization of the Hebron brand, products, and technology.
Mr. Anyuan Sun, Chairman and Chief Executive Office of Hebron, commented, "We are pleased with the reception our exhibition received from companies across the world as we developed the foundations for future cooperation. ACHEMA also gave us the chance to reconnect with old clients to lay the groundwork for future growth and collaboration."
About Hebron Technology Co., Ltd.
Established ináJanuary 2005áand headquartered in Wenzhou City,áZhejiang Province,áChina, Hebron Technology Co., Ltd. ("Hebron" or the "Company") engages in research, development, and manufacture of highly specialized valves and pipe fitting products for use in the pharmaceutical, biological, food and beverage, and other clean industries. The Company also offers its customers comprehensive pipeline design, installation, construction, and ongoing maintenance services as holistic solution services. For more information about the Company, please visit www.xibolun.com.
This press release contains information aboutáHebron'sáview of its future expectations, plans and prospects that constitute forward-looking statements.áActual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property.áHebron encourages you to review other factors that may affect its future results ináHebron'sáregistration statement and in its other filings with the Securities and Exchange Commission.
For more information, please contact:
Hebron Technology Co., Ltd.á Ms. Yingping Chen SecretaryPhone: +86-180-6776-3129
In the United States:
Ascent Investor Relations LLC Ms.áTina XiaoPhone: +1-917-609-0333Email:átina.firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/hebron-technology-co-ltd-exhibited-at-achema-300667017.html
SOURCE Hebron Technology Co., Ltd.
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All